Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.
Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2
(anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the
COVID-19 immunity of the population in French Guiana.
This study is a interventional study that present minimal risks and constraints.
The results of the study will allow estimation of COVID-19 virus infection, severity and
attack rates, as well as inform public health responses and policy decisions in the French
Guiana territory.
Procedure: Blood sample
Blood sample
Inclusion Criteria:
- Person going to a prevention and care center or medical biology analysis laboratory as
part of the care, regardless age, regardless of an acute or previous infection with
COVID-19;
- State of health compatible with a blood sample as defined in the protocol
Exclusion Criteria:
- Inability to consent
- Person under guardianship or curatorship
- Known pathology or a health problem contraindicated with the collect of blood sample.
Centre Hospitalier Andrée Rosemon
Cayenne, French Guiana
Laboratoire de biologie méicale, Institut Pasteur de la Guyane
Cayenne, French Guiana
Laboratoires Eurofins Guyane
Cayenne, French Guiana
Laboratoire de biologie médicale de Kourou
Kourou, French Guiana
Laboratoire de biologie médicale du Centre hospitalier de Saint-Laurent du Maroni
Saint-Laurent du Maroni, French Guiana
Claude Flamand, PhD, Principal Investigator
Institut Pasteur de la Guyane, Head of Epidemiology Unit